Abstract
Background: By considering the high incidence and mortality rate of colorectal cancer (CRC), finding the noninvasive biomarker for detection of patients with cancer is the main purpose of more and more cancer studies. Methods: In this research, the expression level of miR-135b in serum and stool of patients with colorectal cancer was investigated as a diagnostic marker. Using the real-time PCR, the relative expression level of miR-135b in serum and stool in 40 patients with colorectal cancer, paired with 40 healthy controls, was determined. Then its sensitivity and specificity were rated, via ROC curves analysis. Results: Expression levels of miR-135b in serum and stool of CRC patients were 32.4 and 15.7 times higher in serum and stool, compared to that of healthy control respectively (P<0.05). ROC curves analysis exhibited that serum miR-135b levels were powerful in detecting CRC patients from control subjects, with a sensitivity of 92.7% and a specificity of 89.7% (AUC: 0.929). In addition, stool miR-135b levels strongly distinguished CRC patients from control subjects with a sensitivity of 92.7% and a specificity of 87.2% (AUC: 0.919). Conclusions: The results of the current study indicate that serum and stool miR-135b expression levels seem to be used as a potential diagnostic biomarker for CRC patients. However further studies with large sample size are needed for approving the miR-135b as a noninvasive diagnostic biomarker of CRC.
Highlights
Colorectal cancer is one of the most commonly diagnosed malignancies in human and is the second leading cause of cancer death [1]
TNM staging is considered as a standard method in routine use to determine colorectal cancer (CRC) prognosis, in patients with high risk of mortality who could respond to treatment [2]
Statistical analysis of our study showed that the expression level of the miR-135b in serum and stool did not differ significantly, compared to the results of previous studies, which showed that miRNA expression is increased in tumor tissues [4, 34]
Summary
Colorectal cancer is one of the most commonly diagnosed malignancies in human and is the second leading cause of cancer death [1]. By considering the high incidence and mortality rate of colorectal cancer (CRC), finding the noninvasive biomarker for detection of patients with cancer is the main purpose of more and more cancer studies. Methods: In this research, the expression level of miR-135b in serum and stool of patients with colorectal cancer was investigated as a diagnostic marker. Using the real-time PCR, the relative expression level of miR-135b in serum and stool in 40 patients with colorectal cancer, paired with 40 healthy controls, was determined. ROC curves analysis exhibited that serum miR-135b levels were powerful in detecting CRC patients from control subjects, with a sensitivity of 92.7% and a specificity of 89.7% (AUC: 0.929). Conclusions: The results of the current study indicate that serum and stool miR-135b expression levels seem to be used as a potential diagnostic biomarker for CRC patients. Further studies with large sample size are needed for approving the miR-135b as a noninvasive diagnostic biomarker of CRC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
